Drug Search Results
More Filters [+]

Trabedersen

Alternative Names: trabedersen, ap-12009, ap12009, ap 12009, ot-101, ot101, ot 101
Latest Update: 2024-11-06
Latest Update Note: News Article

Product Description

A transforming growth factor (TGF)-beta2 specific phosphorothioate antisense oligodeoxynucleotide with the sequence 5'-CGGCATGTCTATTTTGTA-3', with potential antineoplastic activity. Trebedersen binds to TGF-beta2 mRNA causing inhibition of protein translation, thereby decreasing TGF-beta2 protein levels; decreasing intratumoral TGF-beta2 levels may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trabedersen)

Mechanisms of Action: TGFb Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Isarna
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trabedersen

Countries in Clinic: United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Adenocarcinoma|Myopia, Degenerative|Pancreatic Cancer|Pancreatic Ductal Carcinoma

Phase 2: Mesothelioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OT-01-M201

P2

Not yet recruiting

Mesothelioma

2028-12-01

57%

OT_101_001

P3

Active, not recruiting

Myopia, Degenerative

2027-03-01

38%

STOP-PC

P3

Recruiting

Adenocarcinoma|Pancreatic Ductal Carcinoma|Pancreatic Cancer

2026-06-01

Recent News Events